The Role Of Notch Signalling In Muscular Dystrophy
Funder
National Health and Medical Research Council
Funding Amount
$526,878.00
Summary
Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy, caused by a lack of a protein called dystrophin. Dystrophic muscles are fragile, prone to injury, and have a compromised ability to regenerate after damage. Defective Notch signalling has been implicated in the poor regenerative response of aged muscles and similarly in dystrophy based on our preliminary data. Modulating Notch signalling could therefore delay the onset or slow the progression of DMD.
Targeting The TGF-beta Signalling Pathway To Improve Muscle Growth And Development In Muscular Dystrophy
Funder
National Health and Medical Research Council
Funding Amount
$526,878.00
Summary
Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy. Dystrophic muscles are fragile, prone to injury, and do not regenerate well after injury. Modulating cell signalling pathways that are involved in muscle growth has the potential to attenuate the severity of the dystrophic pathology, to delay the onset or slow the progression of the muscle wasting and weakness, and to improve muscle growth and development in muscular diseases.
Identification Of Neuroprotective Therapies For The Treatment Of Demyelinating Disease
Funder
National Health and Medical Research Council
Funding Amount
$192,300.00
Summary
Brain protection for Multiple Sclerosis (MS) In MS, the immune system repeatedly attacks the brain. Unfortunately, some of the resultant damage cannot be repaired, because it destroys some of the electrical cables (axons). In humans, destruction of axons is permanent and cumulative axonal loss due to repeated attacks ultimately leads to progressive disablity including, paraplegia, dementia, blindness and incontinence. This proposal aims to identify treatments to reduce axonal damage in MS.
Targeting Beta-adrenergic Signalling To Improve Muscle Regeneration In Muscular Dystrophy
Funder
National Health and Medical Research Council
Funding Amount
$473,224.00
Summary
Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy, caused by a lack of a protein called dystrophin. Dystrophic muscles are fragile, prone to injury, and have a compromised ability to regenerate after damage. Modulating pathways regulating beta-adrenergic signalling has potential to attenuate the dystrophic pathology and to delay the onset or slow the progression of the muscle wasting and weakness in muscular dystrophy.